Lipid lowering drugs.
作者信息
O'Connor P, Feely J, Shepherd J
机构信息
Department of Pharmacology and Therapeutics, Trinity College Medical School, St James's Hospital, Dublin.
出版信息
BMJ. 1990 Mar 10;300(6725):667-72. doi: 10.1136/bmj.300.6725.667.
Abstract
摘要
相似文献
1
Lipid lowering drugs.降脂药物。
BMJ. 1990 Mar 10;300(6725):667-72. doi: 10.1136/bmj.300.6725.667.
2
One great leap for lipid lowering drugs.降脂药物的一大飞跃。
Cardiovasc J S Afr. 2002 Sep-Oct;13(5):265-6.
3
Editorial: Lipid-lowering drugs after myocardial infarction.社论：心肌梗死后的降脂药物
Lancet. 1975 Mar 1;1(7905):501-2.
4
Lipid-lowering drug therapies: the evidence.降脂药物疗法：证据
Proc Nutr Soc. 2000 Aug;59(3):423-4. doi: 10.1017/s0029665100000513.
5
[HMG-CoA reductase inhibitors (statin)].[HMG-CoA还原酶抑制剂（他汀类药物）]
Nihon Rinsho. 2007 Jul 28;65 Suppl 7:458-64.
6
[Indications for the pharmacologic treatment of hyperlipidemias].[高脂血症的药物治疗指征]
Rev Clin Esp. 2000 Nov;200(11):622-5.
7
Justifying lipid-lowering therapy in persons >/=65 years of age.
Am J Cardiol. 2002 Dec 15;90(12):1330-2. doi: 10.1016/s0002-9149(02)02872-2.
8
Severely frail elderly patients do not need lipid-lowering drugs.严重虚弱的老年患者不需要降脂药物。
Cleve Clin J Med. 2017 Feb;84(2):131-142. doi: 10.3949/ccjm.84a.15114.
9
Drug therapy for lipid disorders. Selecting appropriate lipid-lowering agents.
Postgrad Med. 1987 Jul;82(1):103-11. doi: 10.1080/00325481.1987.11699898.
10
[Statins].
Nihon Rinsho. 2006 Dec 28;64 Suppl 9:618-21.
引用本文的文献
1
Exploring the Potential of Pyridine Carboxylic Acid Isomers to Discover New Enzyme Inhibitors.探索吡啶羧酸异构体发现新型酶抑制剂的潜力。
Drug Des Devel Ther. 2025 May 20;19:4039-4091. doi: 10.2147/DDDT.S513461. eCollection 2025.
2
Statins for children with familial hypercholesterolemia.用于家族性高胆固醇血症儿童的他汀类药物。
Cochrane Database Syst Rev. 2019 Nov 7;2019(11):CD006401. doi: 10.1002/14651858.CD006401.pub5.
3
Statins for children with familial hypercholesterolemia.用于患有家族性高胆固醇血症儿童的他汀类药物。
Cochrane Database Syst Rev. 2017 Jul 7;7(7):CD006401. doi: 10.1002/14651858.CD006401.pub4.
4
Dietary interventions (plant sterols, stanols, omega-3 fatty acids, soy protein and dietary fibers) for familial hypercholesterolaemia.针对家族性高胆固醇血症的饮食干预措施（植物甾醇、甾烷醇、ω-3脂肪酸、大豆蛋白和膳食纤维）。
Cochrane Database Syst Rev. 2014 Jun 10;2014(6):CD001918. doi: 10.1002/14651858.CD001918.pub3.
5
Pravastatin: a review of its use in elderly patients.普伐他汀：老年患者用药综述
Drugs Aging. 2003;20(14):1061-82. doi: 10.2165/00002512-200320140-00005.
6
Choosing the most appropriate treatment for stable angina. Safety considerations.为稳定型心绞痛选择最合适的治疗方法。安全性考量。
Drug Saf. 1998 Jul;19(1):23-44. doi: 10.2165/00002018-199819010-00003.
7
Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias.阿托伐他汀。其在高脂血症管理中的药理学及治疗潜力综述。
Drugs. 1997 May;53(5):828-47. doi: 10.2165/00003495-199753050-00011.
8
Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.苯扎贝特。其药理学及在血脂异常管理中的应用的最新进展。
Drugs. 1996 Nov;52(5):725-53. doi: 10.2165/00003495-199652050-00008.
9
Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.普伐他汀。对其在冠心病管理中的药理特性和临床疗效的重新评估。
Drugs. 1997 Feb;53(2):299-336. doi: 10.2165/00003495-199753020-00008.
10
Fibrate monotherapy and profound hypoalphalipoproteinaemia.贝特类单药治疗与严重低α脂蛋白血症
Postgrad Med J. 1996 Mar;72(845):189. doi: 10.1136/pgmj.72.845.189.
本文引用的文献
1
Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism.消胆胺促进受体介导的低密度脂蛋白分解代谢。
N Engl J Med. 1980 May 29;302(22):1219-22. doi: 10.1056/NEJM198005293022202.
2
Lipoproteins, cardiovascular disease, and death. The Framingham study.脂蛋白、心血管疾病与死亡。弗雷明汉姆研究
Arch Intern Med. 1981 Aug;141(9):1128-31.
3
Treatment of homozygous familial hypercholesterolaemia with probucol.用普罗布考治疗纯合子家族性高胆固醇血症。
S Afr Med J. 1982 Jul 3;62(1):7-11.
4
Treatment of hypercholesterolemia.
Med Clin North Am. 1982 Mar;66(2):537-50. doi: 10.1016/s0025-7125(16)31434-1.
5
Familial dysbetalipoproteinemia. New aspects of pathogenesis and diagnosis.家族性异常β脂蛋白血症。发病机制与诊断的新进展。
Med Clin North Am. 1982 Mar;66(2):441-54. doi: 10.1016/s0025-7125(16)31429-8.
6
Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen.采用联合用药方案使杂合子家族性高胆固醇血症患者的低密度脂蛋白水平正常化。
N Engl J Med. 1981 Jan 29;304(5):251-8. doi: 10.1056/NEJM198101293040502.
7
The plasma lipoproteins as risk factors: comparison of electrophoretic and ultracentrifugation results.作为风险因素的血浆脂蛋白：电泳和超速离心结果的比较。
Metabolism. 1982 Aug;31(8):773-7. doi: 10.1016/0026-0495(82)90074-9.
8
Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.环丙贝特对高脂蛋白血症患者血清脂蛋白浓度影响的剂量反应研究。
Atherosclerosis. 1982 Apr;42(2-3):229-43. doi: 10.1016/0021-9150(82)90153-8.
9
Ciprofibrate in the therapy of type II hypercholesterolemia. A double-blind trial.环丙贝特治疗II型高胆固醇血症。一项双盲试验。
Atherosclerosis. 1982 Aug;44(2):211-21. doi: 10.1016/0021-9150(82)90115-0.
10
How LDL receptors influence cholesterol and atherosclerosis.低密度脂蛋白受体如何影响胆固醇和动脉粥样硬化。
Sci Am. 1984 Nov;251(5):58-66. doi: 10.1038/scientificamerican1184-58.
Zotero 插件